<DOC>
	<DOC>NCT01818076</DOC>
	<brief_summary>This study will evaluate the long-term safety of botulinum toxin type A for the treatment of moderate to severe crow's feet lines after repeat application.</brief_summary>
	<brief_title>Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate to severe crow's feet lines Female or male, 18 years of age and above and in good general health Women of childbearing potential must agree to use an effective method of birth control during the course of the study Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A Muscle weakness or paralysis, particularly in the area receiving study treatment Active skin disease or irritation at the treatment area Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart Treatment with botulinum toxin type A for crow's feet lines in the last 3 months Chemical peel during the 9 months prior to treatment Use of prescription retinoid products during the 3 months prior to treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>